These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15253477)

  • 61. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients.
    Knoll GA; Sahgal A; Nair RC; Graham J; van Walraven C; Burns KD
    Am J Med; 2002 Feb; 112(2):110-4. PubMed ID: 11835948
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
    Winkelmayer WC; Zhang Z; Shahinfar S; Cooper ME; Avorn J; Brenner BM
    Diabetes Care; 2006 Oct; 29(10):2210-7. PubMed ID: 17003295
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
    Shibasaki Y; Nishiue T; Masaki H; Matsubara H; Iwasaka T
    Nihon Rinsho; 2002 Oct; 60(10):1992-8. PubMed ID: 12397697
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors.
    Ahuja TS; Freeman D; Mahnken JD; Agraharkar M; Siddiqui M; Memon A
    Am J Nephrol; 2000; 20(4):268-72. PubMed ID: 10970978
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ACE inhibitors and ARBs: Managing potassium and renal function.
    Momoniat T; Ilyas D; Bhandari S
    Cleve Clin J Med; 2019 Sep; 86(9):601-607. PubMed ID: 31498767
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on pulmonary function in hypertensive patients.
    Jabbar AS; Neamah NF; Al-Darraji AH
    J Basic Clin Physiol Pharmacol; 2021 Mar; 33(2):207-212. PubMed ID: 33711215
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combined use of enalapril and losartan to reduce proteinuria: a question of safety.
    Ellis D
    Am J Kidney Dis; 2002 Jan; 39(1):209-11. PubMed ID: 11774126
    [No Abstract]   [Full Text] [Related]  

  • 68. Severe hyperkalemia during very-low-calorie diets and angiotensin converting enzyme use.
    Stoltz ML; Andrews CE
    JAMA; 1990 Dec; 264(21):2737-8. PubMed ID: 2172575
    [No Abstract]   [Full Text] [Related]  

  • 69. [Treatment of post kidney transplantation erythrocytosis (PTE) with ACE inhibitors].
    Morale W; Puliatti C; Veroux P; Veroux M; Valvo C; Cappello D; Puliatti D; Francesco L
    Minerva Urol Nefrol; 2002 Jun; 54(2):145-8. PubMed ID: 12070465
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Adverse effects of lisinopril.
    Lancet; 1989 Feb; 1(8635):434-5. PubMed ID: 2563805
    [No Abstract]   [Full Text] [Related]  

  • 71. [Severe hyperkalemia associated to the use of losartan and spironolactone: case report].
    Kauffmann R; Orozco R; Venegas JC
    Rev Med Chil; 2005 Aug; 133(8):947-52. PubMed ID: 16163434
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hyperkalemia with concomitant watery diarrhea: an unusual association.
    Taylor JG; Zwillich CW; Kaehny WD; Levi M; Popovtzer MM
    Am J Kidney Dis; 2003 Aug; 42(2):E9-12. PubMed ID: 12900845
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Possible Advantages Deriving from Patiromer Use in Hypertensive Patients Made Hyperkalemic by Renin-Angiotensin-Aldosterone Blocking Agents.
    Borghi C; Ferri C; Pontremoli R; Sechi L; Grassi G
    High Blood Press Cardiovasc Prev; 2021 Nov; 28(6):555-559. PubMed ID: 34709583
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Model for End-stage Liver Disease score is potentially a useful predictor of hyperkalemia occurrence among hospitalized angiotensin receptor blocker users.
    Sheen SS; Park RW; Yoon D; Shin GT; Kim H; Park IW
    J Clin Pharm Ther; 2015 Feb; 40(1):48-54. PubMed ID: 25328056
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study.
    Espinel E; Joven J; Gil I; Suñé P; Renedo B; Fort J; Serón D
    BMC Res Notes; 2013 Aug; 6():306. PubMed ID: 23915518
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Blood pressure medications: ACE-I/ARB and chronic kidney disease.
    Han H
    J Ren Nutr; 2013 Nov; 23(6):e105-7. PubMed ID: 24209897
    [No Abstract]   [Full Text] [Related]  

  • 77. [Acute kidney failure and losartan: a recently observed event of antagonists of angiotensin II AT1 receptors].
    Dionisio P; Valenti M; Caramello E; Bergia R; Cravero R; Berto IM; Agostini B; Monaci G; Bajardi P
    Minerva Urol Nefrol; 2000 Sep; 52(3):123-5. PubMed ID: 11227361
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The ACE Inhibitor Lisinopril Stimulates Melanoma Cell Invasiveness by Inducing MMP2 Secretion.
    Becker Y; Stock C
    Cell Physiol Biochem; 2022 Sep; 56(5):457-483. PubMed ID: 36057984
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Syncope caused by iatrogenic hyperkalemia.
    Giancaspro G; Suppa M; Genuini I; Caselli S; Fedele F
    J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):72-4. PubMed ID: 19708228
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A true MI?
    Sharma AK; Heist K; Russell G; Krahn T; Ferrell M
    Am J Med; 2011 Jul; 124(7):608-10. PubMed ID: 21531370
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.